\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe evaluation of proposals submitted to the first wave of calls (November 2021-February 2022) under the Digital Europe programme has been completed.
The European Commission recently informed the applicants about the evaluation results for their proposals. It is expected that grant agreements will be signed by 22 November 2022.
In total, 11 consortia with Flemish participants have been chosen to negotiate grant agreements with the Commission; a twelfth consortium with a Flemish organisation as participant is on the reserve list. Only two consortia with Flemish participants have no chance of receiving funding in this round of calls. The winning consortia submitted proposals for different sectoral data spaces, AI and data infrastructures, digital skills training programmes and projects applying digital technologies in different sectors.
The next Digital Europe calls are expected to open by the end of September 2022.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
